Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

Moderna has said it will open a new R&D and manufacturing facility in the UK which could lead to improved access by NHS patients to mRNA-based vaccines and drug treatments. The facility is the ...

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...

A social media post claims that Moderna’s CEO confessed to creating a COVID vaccine before the pandemic. After fact checking, we found that the claim is false. According to an Instagram post, “Moderna ...